These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

629 related articles for article (PubMed ID: 30649747)

  • 21. Intracellular trafficking of new anticancer therapeutics: antibody-drug conjugates.
    Kalim M; Chen J; Wang S; Lin C; Ullah S; Liang K; Ding Q; Chen S; Zhan J
    Drug Des Devel Ther; 2017; 11():2265-2276. PubMed ID: 28814834
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Clinical pharmacology strategies in supporting drug development and approval of antibody-drug conjugates in oncology.
    Liu SN; Li C
    Cancer Chemother Pharmacol; 2021 Jun; 87(6):743-765. PubMed ID: 33792763
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Antibody drug conjugates under investigation in phase I and phase II clinical trials for gastrointestinal cancer.
    Leal AD; Krishnamurthy A; Head L; Messersmith WA
    Expert Opin Investig Drugs; 2018 Nov; 27(11):901-916. PubMed ID: 30359534
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Antibody-drug conjugates: the new generation of biotechnological therapies against cancer.
    Melgarejo-Rubio G; Pérez-Tapia SM; Medina-Rivero E; Velasco-Velázquez MA
    Gac Med Mex; 2020; 156(3):228-235. PubMed ID: 32538994
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Antibody-targeted drugs for the therapy of cancer.
    Pietersz GA; Krauer K
    J Drug Target; 1994; 2(3):183-215. PubMed ID: 7812691
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Antibody conjugate therapeutics: challenges and potential.
    Teicher BA; Chari RV
    Clin Cancer Res; 2011 Oct; 17(20):6389-97. PubMed ID: 22003066
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Expert consensus on the clinical application of antibody drug conjugates in the treatment of malignant tumors (2023 edition)].
    ; ; ;
    Zhonghua Zhong Liu Za Zhi; 2023 Sep; 45(9):741-762. PubMed ID: 37460440
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Naptumomab estafenatox: a new immunoconjugate.
    Robinson MK; Alpaugh RK; Borghaei H
    Expert Opin Biol Ther; 2010 Feb; 10(2):273-9. PubMed ID: 20053143
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Resistance to Antibody-Drug Conjugates.
    García-Alonso S; Ocaña A; Pandiella A
    Cancer Res; 2018 May; 78(9):2159-2165. PubMed ID: 29653942
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Engineered anti-CD70 antibody-drug conjugate with increased therapeutic index.
    McDonagh CF; Kim KM; Turcott E; Brown LL; Westendorf L; Feist T; Sussman D; Stone I; Anderson M; Miyamoto J; Lyon R; Alley SC; Gerber HP; Carter PJ
    Mol Cancer Ther; 2008 Sep; 7(9):2913-23. PubMed ID: 18790772
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Comprehensive review on the elaboration of payloads derived from natural products for antibody-drug conjugates.
    Lu N; Wu J; Tian M; Zhang S; Li Z; Shi L
    Eur J Med Chem; 2024 Mar; 268():116233. PubMed ID: 38408390
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Monoclonal Antibodies, Small Molecule Inhibitors and Antibody-drug Conjugates as HER2 Inhibitors.
    Li XF; Liu CF; Rao GW
    Curr Med Chem; 2021; 28(17):3339-3360. PubMed ID: 32900344
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Antibody-drug conjugates for cancer.
    Chau CH; Steeg PS; Figg WD
    Lancet; 2019 Aug; 394(10200):793-804. PubMed ID: 31478503
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Extracellular vesicles as modifiers of antibody-drug conjugate efficacy.
    Barok M; Puhka M; Yazdi N; Joensuu H
    J Extracell Vesicles; 2021 Feb; 10(4):e12070. PubMed ID: 33613875
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Targeted cancer therapy: conferring specificity to cytotoxic drugs.
    Chari RV
    Acc Chem Res; 2008 Jan; 41(1):98-107. PubMed ID: 17705444
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The next generation of antibody-drug conjugates comes of age.
    Beck A; Haeuw JF; Wurch T; Goetsch L; Bailly C; Corvaïa N
    Discov Med; 2010 Oct; 10(53):329-39. PubMed ID: 21034674
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Novel linkers and connections for antibody-drug conjugates to treat cancer and infectious disease.
    Pillow TH
    Pharm Pat Anal; 2017 Jan; 6(1):25-33. PubMed ID: 28155578
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Antibody-Drug Conjugates: The New Frontier of Chemotherapy.
    Ponziani S; Di Vittorio G; Pitari G; Cimini AM; Ardini M; Gentile R; Iacobelli S; Sala G; Capone E; Flavell DJ; Ippoliti R; Giansanti F
    Int J Mol Sci; 2020 Jul; 21(15):. PubMed ID: 32752132
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Antibody-Drug Conjugates and Small Molecule-Drug Conjugates: Opportunities and Challenges for the Development of Selective Anticancer Cytotoxic Agents.
    Casi G; Neri D
    J Med Chem; 2015 Nov; 58(22):8751-61. PubMed ID: 26079148
    [TBL] [Abstract][Full Text] [Related]  

  • 40. New Technologies Bloom Together for Bettering Cancer Drug Conjugates.
    Jin Y; Edalatian Zakeri S; Bahal R; Wiemer AJ
    Pharmacol Rev; 2022 Jul; 74(3):680-711. PubMed ID: 35710136
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 32.